Australia Markets closed

Mindset Pharma Inc. (MSSTF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.5302-0.0438 (-7.63%)
As of 01:16PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close0.5740
Open0.5571
BidN/A x N/A
AskN/A x N/A
Day's range0.5097 - 0.5632
52-week range0.2959 - 1.0718
Volume27,613
Avg. volume46,906
Market cap46.609M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-0.1760
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    The McQuade Center for Strategic Research and Development and Mindset Pharma Collaborate to Develop Psychedelic Medicines

    PRINCETON, N.J., Jan. 05, 2022 (GLOBE NEWSWIRE) -- The McQuade Center for Strategic Research and Development, LLC (MSRD), a member of the global Otsuka family of pharmaceutical companies, and Mindset Pharma Inc. (Mindset) (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) today announce a collaboration that will support the development of psychedelic medicines. MSRD has made a strategic investment to support the discovery and development of novel chemical entity assets of Mindset, a drug discovery and develo

  • GlobeNewswire

    Mindset to Participate in the H.C. Wainwright BioConnect Conference on January 10-13, 2022

    TORONTO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, today announced that it will participate in the H.C. Wainwright BioConnect Conference to be hosted virtually on January 10-13, 2022. A corporate presentation from James La

  • GlobeNewswire

    Mindset Pharma Recaps 2021 Milestones and Highlights

    Evolving Pipeline of Psychedelic Compounds Focused on Improved Efficacy and Safety Advancing MSP-1014 as First Lead Drug Clinical Candidate to IND-Enabling Studies TORONTO, Dec. 30, 2021 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, today p